Journal of Clinical Endocrinology & Metabolism, Vol 57, 732-736, Copyright © 1983 by Endocrine Society

ARTICLES

Site of action of low dose ketoconazole on androgen biosynthesis in men

RJ Santen, H Van den Bossche, J Symoens, J Brugmans and R DeCoster

Ketoconazole inhibits testosterone biosynthesis in men, but the exact site of its action on the androgen pathway remains to be established. To examine this question, we measured several steroids in the androgen and glucocorticoid pathways in normal men before and after receiving either a single dose of 200 mg ketoconazole or placebo in a cross-over randomized trial. Total and free plasma testosterone fell to levels 60% below basal within 4-8 h (P less than 0.02 in all) and then returned to control concentrations by 24 h after drug administration. The transient alterations of plasma testosterone correlated well with ketoconazole blood levels, which peaked at 2 h and fell exponentially thereafter. A compensatory increase in plasma LH at 24 h in the drug but not placebo group was consistent with the decrease in plasma testosterone. The levels of plasma androstenedione paralleled those of testosterone in the ketoconazole-treated subjects. In marked contrast, plasma 17 alpha- hydroxyprogesterone increased at 4-8 h (all P less than 0.02) before returning to basal values at 24 h. This rise in precursor with fall in product steroid implicated an effect of ketoconazole on the C17-20 lyase enzyme. This conclusion was supported by the highly significant increase in the ratio of plasma 17 alpha-hydroxyprogesterone to androstenedione observed between 2 and 24 h after drug administration. The effect of ketoconazole at this dose level appeared relatively specific, since no decrements in plasma cortisol or 11-desoxycortisol were found. During chronic administration of 200 mg ketoconazole daily, decrements of plasma testosterone 2-4 h after drug administration were minimal and documented only by paired comparisons within subjects but not by unpaired tests between normal men and men receiving drug. The lack of major effects on testosterone levels long term at this dosage probably explain why few androgen-related side effects with this drug were previously reported. Ketoconazole, therefore, represents another compound with relatively selective effects on a cytochrome P-450- mediated steroid hydroxylation step, namely that involved with C17-20 lyase.

This article has been cited by other articles:

				Y. Tani, P. M. Foster, R. C. Sills, P. C. Chan, S. D. Peddada, and A. Nyska Epididymal Sperm Granuloma Induced by Chronic Administration of 2-Methylimidazole in B6C3F1 Mice Toxicol Pathol, April 1, 2005; 33(3): 313 - 319. [Abstract] [Full Text] [PDF]

				D. MORRIS and A. GROSSMAN The Medical Management of Cushing's Syndrome Ann. N.Y. Acad. Sci., September 1, 2002; 970(1): 119 - 133. [Abstract] [Full Text] [PDF]

				C.-Y. Chang, P. J. Walther, and D. P. McDonnell Glucocorticoids Manifest Androgenic Activity in a Cell Line Derived from a Metastatic Prostate Cancer Cancer Res., December 1, 2001; 61(24): 8712 - 8717. [Abstract] [Full Text] [PDF]

				J. A. Schnorr, M. J. Bray, and J. D. Veldhuis Aromatization Mediates Testosterone's Short-Term Feedback Restraint of 24-Hour Endogenously Driven and Acute Exogenous Gonadotropin-Releasing Hormone-Stimulated Luteinizing Hormone and Follicle-Stimulating Hormone Secretion in Young Men J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2600 - 2606. [Abstract] [Full Text] [PDF]

				F. J. Hayes, S. DeCruz, S. B. Seminara, P. A. Boepple, and W. F. Crowley Jr. Differential Regulation of Gonadotropin Secretion by Testosterone in the Human Male: Absence of a Negative Feedback Effect of Testosterone on Follicle-Stimulating Hormone Secretion J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 53 - 58. [Abstract] [Full Text]

				V. S. Wilson and G. A. LeBlanc The Contribution of Hepatic Inactivation of Testosterone to the Lowering of Serum Testosterone Levels by Ketoconazole Toxicol. Sci., March 1, 2000; 54(1): 128 - 137. [Abstract] [Full Text] [PDF]

				E. W. Leschek, J. Jones, K. M. Barnes, S. C. Hill, and G. B. Cutler Jr. Six-Year Results of Spironolactone and Testolactone Treatment of Familial Male-Limited Precocious Puberty with Addition of Deslorelin after Central Puberty Onset J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 175 - 178. [Abstract] [Full Text]

				R. Dumaine, M.-L. Roy, and A. M. Brown Blockade of HERG and Kv1.5 by Ketoconazole J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 727 - 735. [Abstract] [Full Text]

				M. Honda, G. S. Tint, A. Honda, L. B. Nguyen, T. S. Chen, and S. Shefer 7-Dehydrocholesterol down-regulates cholesterol biosynthesis in cultured Smith-Lemli-Opitz syndrome skin fibroblasts J. Lipid Res., March 1, 1998; 39(3): 647 - 657. [Abstract] [Full Text]

				J. A. Como and W. E. Dismukes Oral Azole Drugs as Systemic Antifungal Therapy N. Engl. J. Med., January 27, 1994; 330(4): 263 - 272. [Full Text]